Albumin is given during dialysis as an intravenous infusion, most commonly as 100 mL of 25% albumin (delivering 25 grams of protein), either at the start of the dialysis session to prevent blood-pressure drops or during the session to treat a drop that has already occurred. The practice is widespread but surprisingly contentious: the evidence supporting it depends heavily on which concentration is used, what the patient’s baseline albumin level is, and whether saline alone would have done the same job. Getting the details right matters for both patient safety and cost.
Why Albumin Gets Used During Dialysis
The core problem albumin aims to solve is intradialytic hypotension, the sudden blood-pressure drops that occur in a large share of hemodialysis sessions. During ultrafiltration, the machine removes excess fluid from the bloodstream. As blood volume shrinks, the body compensates by pulling fluid from tissues back into the bloodstream, a process called plasma refilling. The speed of that refilling depends partly on oncotic pressure, the “pull” that proteins (especially albumin) exert inside blood vessels. When a patient’s albumin is already low, that pull is weaker, and the body cannot refill fast enough to keep up with fluid removal. Blood pressure drops, the session gets interrupted, and fluid removal targets are missed.
Infusing albumin in theory boosts that oncotic pull, helping the vascular space refill faster and keeping blood pressure stable so that the prescribed amount of fluid can be removed safely.1PubMed Central. A randomized trial of albumin infusion to prevent intradialytic hypotension in hospitalized hypoalbuminemic patients The catch, as a review in the Clinical Journal of the American Society of Nephrology noted, is that albumin does not expand plasma volume as powerfully as its oncotic properties alone would predict.2PubMed Central. Intravenous Albumin for Mitigating Hypotension and Augmenting Ultrafiltration during Kidney Replacement Therapy Part of the infused albumin leaks out of the bloodstream within hours, blunting its theoretical advantage.
Concentration Matters More Than You Might Expect
Albumin comes in two standard concentrations: 5% (roughly matching the protein content of normal blood plasma) and 25% (a hyper-concentrated solution sometimes called “salt-poor albumin”). These are not interchangeable for dialysis purposes, and the clinical evidence splits sharply between them.
A randomized, double-blind crossover trial in 72 chronic hemodialysis patients compared 5% albumin head-to-head with normal saline for treating blood-pressure drops that had already happened. The results were essentially a tie across nearly every measure: percentage of target fluid removal achieved, post-dialysis blood pressure, nursing time, treatment failures, and recurrence of hypotension were not significantly different between the two groups. The study concluded that 5% albumin offered no advantage over saline for acute treatment of intradialytic hypotension in chronic patients.3PubMed. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension A Cochrane systematic review that assessed the available evidence found only this one trial meeting its inclusion criteria and reached the same conclusion: no convincing difference between 5% albumin and saline.4Cochrane Database of Systematic Reviews. Human albumin for hypotension in haemodialysis patients
The picture changes when you look at 25% albumin used preventively in patients whose blood albumin is already low. A crossover trial in hospitalized patients with low albumin levels randomized them to receive either 100 mL of 25% albumin or 100 mL of normal saline at the start of each dialysis session. Using the standard definition from the Kidney Disease Outcomes Quality Initiative, the rate of intradialytic hypotension roughly halved with albumin compared to saline (about 7% of sessions versus 15%). The lowest systolic blood pressure recorded during sessions was also higher in the albumin group (around 90 mmHg compared with 83 mmHg), and more fluid was successfully removed.1PubMed Central. A randomized trial of albumin infusion to prevent intradialytic hypotension in hospitalized hypoalbuminemic patients
The takeaway: 5% albumin, when used to rescue a blood-pressure drop that has already occurred, does not clearly outperform a bag of saline. But 25% albumin, given at the start of the session in patients who are already protein-depleted, shows a more convincing benefit. That distinction shapes most of the practical protocols in use today.
Typical Dosing and When to Infuse
The most commonly studied regimen is 100 mL of 25% albumin, which delivers 25 grams. This dose appears consistently across published trials. The infusion is given through the dialysis circuit’s venous line, either at the beginning of the session or in response to a hypotensive episode, depending on the clinical goal.
When the aim is prevention, the albumin is infused at session start, usually over 15 to 30 minutes. In the crossover trial of hospitalized patients described above, the 25% albumin was administered at the initiation of each dialysis session, with vital signs and ultrafiltration rate monitored every 15 to 30 minutes throughout.1PubMed Central. A randomized trial of albumin infusion to prevent intradialytic hypotension in hospitalized hypoalbuminemic patients
When the aim is rescue, many units follow a stepwise approach: saline first, albumin second. A common protocol calls for 200 mL of normal saline infused over about 10 minutes when blood pressure drops. If the patient remains hypotensive 10 minutes after the saline bolus, 100 mL of 25% albumin is given. If blood pressure still does not recover, a second dose of albumin can follow 10 minutes later, at which point the nephrologist is consulted. This saline-first approach was shown in one institutional study to cut total albumin use by more than half while reversing hypotensive episodes at the same rate as less structured protocols.
Who Benefits Most
The patients most likely to benefit are those whose serum albumin is already low. This makes intuitive sense: if the problem is weak oncotic pull, adding concentrated albumin to a depleted system has more room to make a difference. A survey of nephrologists and intensivists confirmed that clinicians act on this logic. Respondents were far more likely to prescribe albumin when the patient’s serum albumin was below 20 g/L compared to above 30 g/L (about 63% versus 4%).5Kidney International Reports. The Use of I.V. Albumin During Kidney Replacement Therapy: A Survey of Nephrologists and Intensivists
Critically ill patients in the ICU represent another group where albumin use is common. The same survey found that intensivists were significantly more likely than nephrologists to prescribe albumin during dialysis (about 60% versus 48%), and that use jumped substantially when patients were on vasopressors, the drugs used to support blood pressure in the sickest ICU patients.5Kidney International Reports. The Use of I.V. Albumin During Kidney Replacement Therapy: A Survey of Nephrologists and Intensivists In these patients, the stakes of a blood-pressure crash during dialysis are higher, and clinicians are more willing to reach for albumin despite the ambiguous trial data.
For stable outpatients on chronic hemodialysis who have normal albumin levels and occasional mild blood-pressure dips, the evidence does not support routine albumin use. Saline boluses, adjusting the ultrafiltration rate, cooling the dialysate, or extending the session length are first-line approaches that avoid the cost and marginal risks of albumin infusion.
Cost and the Push Toward Stewardship
Human albumin is a blood-derived product and is expensive relative to saline. A single 100 mL vial of 25% albumin can cost several times what a bag of normal saline does, and when it is used routinely across multiple sessions per week in a busy dialysis unit, the expense adds up quickly. This has driven interest in albumin-sparing protocols.
Institutions that have implemented stepwise algorithms, where saline is tried first and albumin reserved for refractory drops, have seen substantial reductions in albumin consumption without sacrificing the rate at which hypotensive episodes are successfully reversed. One single-center study found that implementing such an algorithm cut total albumin use by nearly 60% and reduced associated costs by a similar margin, while the success rate for reversing hypotension remained essentially unchanged at roughly 90%. The argument is not that albumin should never be used, but that in many cases saline works just as well for the acute episode, and albumin should be reserved for the patients who truly need it.
Safety Considerations
Albumin infusions are generally well tolerated, but they are not risk-free. A review of adverse reactions to human serum albumin identified the cardiovascular and pulmonary systems as the areas most vulnerable to complications, particularly from excessive administration. Fluid overload and worsening pulmonary edema are the most practical concerns during dialysis, especially if albumin is given too rapidly or in patients who are not significantly volume-depleted. Hypersensitivity reactions can occur and may be severe, though they are infrequent. Other potential effects include changes in coagulation parameters and alterations in trace metal levels.6PubMed. Adverse reactions to human serum albumin
In the dialysis setting, the risk of fluid overload is somewhat offset by the fact that ultrafiltration is actively removing fluid at the same time. Still, giving a bolus of concentrated albumin at the start of a session means the patient’s intravascular volume spikes briefly before ultrafiltration catches up. In patients with compromised heart function, that spike can be enough to cause shortness of breath or elevated filling pressures. The clinical team typically monitors for these signs closely in the first 30 minutes.
Albumin Loss Through the Dialyzer Membrane
An entirely separate albumin issue during dialysis involves the membrane itself. All dialyzers allow some proteins to pass through, and albumin losses vary dramatically depending on the type of membrane and the mode of treatment. Standard high-flux hemodialysis typically results in minimal albumin loss, usually under 2 grams per four-hour session. But hemodiafiltration, particularly in post-dilution mode at higher flow rates, can push losses much higher. One study evaluating eight different high-flux dialyzers in post-dilution hemodiafiltration found that albumin losses jumped from under 2 grams at a filtration rate of 30 mL/min to as high as 7 grams at 90 mL/min, with wide variation between different dialyzer brands.7PubMed Central. Albumin losses during hemodiafiltration: all dialyzers are not created equal – a case report
Newer medium cut-off membranes, designed to remove larger waste molecules more effectively, also allow more albumin through compared with traditional high-flux membranes. Research comparing the two found that high-flux membranes used with standard hemodialysis had an albumin-to-total-protein loss ratio of only about 10%, while medium cut-off membranes showed ratios in the range of 50% to 60%, closer to the proportion of albumin in blood itself.8PubMed Central. Removal of Middle Molecules and Dialytic Albumin Loss: A Cross-over Study of Medium Cutoff and High-Flux Membranes with Hemodialysis and Hemodiafiltration The practical implication is that patients on these newer modalities may become hypoalbuminemic faster, which in turn could increase their need for albumin supplementation to maintain hemodynamic stability during future sessions. It is a somewhat circular problem that dialysis teams need to stay aware of.
Raising Albumin Levels Through Nutrition Rather Than Infusion
Low serum albumin in dialysis patients is not just a hemodynamic problem; it is a marker of poor nutrition and chronic inflammation, both of which predict worse outcomes. Giving albumin intravenously to prop up blood pressure during a session does nothing to address the underlying protein-calorie malnutrition that many dialysis patients face. For that, some centers use intradialytic parenteral nutrition (IDPN), an infusion of amino acids, lipids, and glucose delivered through the dialysis circuit during the session itself.
A large retrospective analysis of over 1,600 patients who received IDPN during in-center hemodialysis found that after six months, serum albumin levels rose by an average of about 0.33 g/dL, and roughly 82% of patients achieved a meaningful increase of at least 0.2 g/dL.9PubMed Central. Intradialytic Parenteral Nutrition during In-Center Hemodialysis of Patients Leads to Increase in Albumin without Compromising Safety: Retrospective Analysis These improvements happened because the body was manufacturing more of its own albumin from the amino acid building blocks provided, rather than receiving albumin directly. If a patient’s low albumin is driven by malnutrition rather than acute illness, addressing the nutritional deficit may reduce the need for albumin infusions over time.
Dialysis Patients With Liver Disease
Patients who need dialysis and also have advanced liver disease, such as decompensated cirrhosis, present a particularly challenging situation. The liver is where albumin is produced, so these patients are often severely hypoalbuminemic for reasons that neither nutrition nor short-term infusions can fix. In the broader hepatology literature, long-term albumin supplementation (for instance, 20 grams twice a week) has been associated with lower mortality, fewer hospitalizations for hepatic encephalopathy, and reduced accumulation of ascites in patients with decompensated cirrhosis.10Journal of Hepatology. Long-term albumin administration in decompensated cirrhosis
For these patients on dialysis, the rationale for albumin infusion during sessions is stronger than in the general dialysis population. Their baseline oncotic pressure is chronically low, plasma refilling is consistently impaired, and they tolerate ultrafiltration poorly. Many nephrologists will use albumin more liberally in this group, sometimes at every session, recognizing that the underlying liver dysfunction makes the hemodynamic problem persistent rather than episodic. The evidence base for this specific intersection, dialysis plus cirrhosis, remains thin, and most clinical decisions are extrapolated from the hepatology trials and from the general intradialytic hypotension literature. It is one of those areas where clinical judgment fills the gap that trials have not yet closed.
Practical Monitoring During and After Infusion
When albumin is infused during a dialysis session, the clinical team watches for a few specific things. Vital signs, particularly blood pressure and heart rate, are typically checked every 15 to 30 minutes.1PubMed Central. A randomized trial of albumin infusion to prevent intradialytic hypotension in hospitalized hypoalbuminemic patients Any signs of respiratory distress, chest tightness, or new wheezing can signal fluid overload or a rare allergic reaction and warrant stopping the infusion. The ultrafiltration rate may be adjusted upward slightly after the albumin is given, since the improved oncotic pressure theoretically allows faster fluid removal without destabilizing blood pressure.
Post-session, there is no need for special monitoring beyond the usual. Serum albumin levels are not typically rechecked immediately after an infusion, because the infused albumin redistributes over several hours, and a spot check right after dialysis would overestimate the lasting effect. Trends in pre-dialysis serum albumin drawn at the start of subsequent sessions give a better picture of whether repeated infusions, nutritional support, or treatment of the underlying cause is moving things in the right direction.